AbCellera Biologics (ABCL) Cash from Operations (2020 - 2025)
AbCellera Biologics' Cash from Operations history spans 6 years, with the latest figure at 34743000.0 for Q4 2025.
- For the quarter ending Q4 2025, Cash from Operations fell 334.29% year-over-year to 34743000.0, compared with a TTM value of 131295000.0 through Dec 2025, down 20.95%, and an annual FY2025 reading of 131295000.0, down 20.95% over the prior year.
- Cash from Operations for Q4 2025 was 34743000.0 at AbCellera Biologics, up from 52594000.0 in the prior quarter.
- The five-year high for Cash from Operations was 273015000.0 in Q2 2022, with the low at 126786000.0 in Q3 2022.
- Average Cash from Operations over 5 years is 11910800.0, with a median of 14133000.0 recorded in 2021.
- Year-over-year, Cash from Operations surged 14438.35% in 2021 and then crashed 27147.17% in 2024.
- Tracing ABCL's Cash from Operations over 5 years: stood at 16712000.0 in 2021, then skyrocketed by 284.97% to 30912000.0 in 2022, then crashed by 163.44% to 19611000.0 in 2023, then surged by 59.21% to 8000000.0 in 2024, then crashed by 334.29% to 34743000.0 in 2025.
- Per Business Quant, the three most recent readings for ABCL's Cash from Operations are 34743000.0 (Q4 2025), 52594000.0 (Q3 2025), and 32404000.0 (Q2 2025).